Biotech: Blood samples are raw materials for virus research and development. by Amy Stulick, Staff Reporter As pharmaceutical labs race to develop a vaccine for COVID-19, biomaterial for researchers has become increasingly valuable. That works to the advantage of Sanguine Biosciences in Sherman Oaks, which provides blood, tissue, plasma, and other biologic material for R&D.
After recovering from Covid-19 in April, Tom Hanks was so chuffed by the prospect of his plasma being used for medical science that he suggested calling the results a “Hank-cine.” He is not alone. Other former patients are equally enthusiastic about donating blood to the research effort.
Research on the human microbiome has burgeoned in recent years. Microbiome imbalances have been linked to chronic conditions, such as diabetes, cardiovascular disease, and depression. But scientists have also uncovered evidence of the microbiome’s crucial role in infectious diseases, including COVID-19, pointing to it as a promising target for treating them.
Study-patient recruitment and retention continue to be significant challenges in medical research, and even more so, during the COVID-19 pandemic. The at-home isolation and social distancing orders for millions of Americans is a vital element to slow the COVID-19 pandemic, but the global pandemic has the potential to disrupt and delay vital research.
In 2000, Malcolm Gladwell’s The Tipping Point became a runaway bestseller by describing the factors that fuel an epidemic, and how the world suddenly becomes a different place as it reaches the inflection point. He discusses epidemics as spreading quickly like a virus, causing people to start behaving differently, triggering contagiousness, whether it applies to fashion trends, the uptake of cell phones, or the spread of disease.
Over the past twenty years, the world has faced several infectious disease outbreaks including; Ebola, Influenza A (H1N1), SARS, MERS, Zika virus and now COVID-19. With over 200k deaths worldwide, COVID-19 has brought an enormous strain on our health resources, but also has had a massive impact on human health and the economy.
The global search for a treatment targeting the novel coronavirus has led to an unlikely potential savior: a cocoa-colored llama named Winter, whose blood could hold a weapon to blunt the virus. She lives at a research farm in Belgium with about 130 other llamas and alpacas.
COVID-19 has put the biopharma industry into a tailspin – big pharma, biotech and small startups are all emerging in the development of a treatment and vaccine for this pandemic. Will COVID-19 change the current R&D landscape and create a new norm for the biopharma industry?
WBZ | CBS Boston – Lara Woolfson’s COVID-19 story and her participation with Sanguine for her in-home blood sample collection. Transcript: Headline News: Live from the Channel 4 Studios in Boston, this is WBZ news at 5:30. Liam Martin: Well for a photographer from Boston who has already recovered from the coronavirus is hoping that her fight with it will help others recover as well.
One of the challenges to securing the participation of patients in clinical trials can be simple geography. Sanguine Biosciences is seeking to tear down that barrier to participation by using mobile technology to bring clinical trials to patients. The company recently partnered with Vir Biotechnology to complete a COVID-19 clinical study aimed at better understanding the biology of the disease by sending healthcare personnel to collect blood samples from patients at their homes.